ArticlePakistan journal of medical sciences2025
Effect of Pomalidomide-based regimen on the treatment of patients with first-relapsed multiple myeloma and analysis of prognostic factors.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the effect and safety of pomalidomide (POM)-based regimen on the treatment of patients with first-relapsed multiple myeloma (MM), and to analyze the factors affecting prognosis. Methods: This was retrospective study. Thirty-eight patients with first-relapsed MM admitted to Hematology Department of Beijing Shunyi Hospital from January 2020 to June 2023 were included and divided into observation group (n=20) and control group (n=18) according to treatment regimens. Record the time of progressive disease (PD), death, adverse reactions, analyze the progression-free survival (PFS) and overall survival (OS). Results: The overall response rate of the observation group was 85.00%, was higher than that of 55.56% in the control group (c2=3.993, Conclusion: POM-based regimen can significantly improve the PFS and overall response rate in patients with first-relapsed MM. The use of POM is a protective factor, extramedullary plasmacytoma, risk stratification, and LDH>240 U/L are independent risk factors for PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.